12 Month Price Forecast For ASMB
Distance to ASMB Price Forecasts
ASMB Price Momentum
๐ค Considering Assembly Biosciences (ASMB)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 11:09 AM UTC
ASMB Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, ASMB has a consensus that is bullish. The median price target is $35.50, with forecasts ranging from $35.00 to $36.00. Currently, there are 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With ASMB currently trading at $14.21, the median price forecast suggests a 149.8% upside. The most optimistic forecast comes from at , projecting a 153.3% upside, while Dennis Ding at Jefferies provides the most conservative target, suggesting a 146.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ASMB Analyst Consensus
ASMB Price Target Range
Latest ASMB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ASMB.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 27, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
Sep 24, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
Sep 20, 2024 | Jefferies | Dennis Ding | Buy | Upgrade | $35.00 |
Jun 20, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
Jun 13, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
Apr 1, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
Mar 24, 2023 | HC Wainwright & Co. | Ed Arce | Neutral | Maintains | $1.50 |
Nov 16, 2022 | Mizuho | Salim Syed | Buy | Maintains | $3.00 |
Oct 24, 2022 | Truist Securities | Nicole Germino | Hold | Downgrade | $2.00 |
Apr 1, 2022 | Truist Securities | Nicole Germino | Buy | Maintains | $12.00 |
Sep 13, 2021 | HC Wainwright & Co. | Neutral | Initiates | $0.00 | |
Sep 2, 2021 | William Blair | Market Perform | Downgrade | $0.00 | |
May 10, 2021 | SVB Leerink | Market Perform | Maintains | $7.00 | |
Mar 23, 2021 | SVB Leerink | Geoffrey Porges | Market Perform | Downgrade | $8.00 |
Nov 6, 2020 | Jefferies | Hold | Downgrade | $0.00 | |
Oct 19, 2020 | Truist Securities | Buy | Initiates | $0.00 | |
Jul 8, 2020 | SVB Leerink | Outperform | Maintains | $38.00 | |
Oct 16, 2019 | Mizuho | Buy | Initiates | $0.00 | |
Oct 8, 2018 | B. Riley FBR | Buy | Upgrade | $0.00 | |
Oct 8, 2018 | B. Riley Securities | Madhu Kumar | Buy | Upgrade | $42.00 |
Stocks Similar to Assembly Biosciences Inc
The following stocks are similar to Assembly Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Assembly Biosciences Inc (ASMB) Financial Data
Assembly Biosciences Inc has a market capitalization of $90.32M with a P/E ratio of -1.1x. The company generates $21.48M in trailing twelve-month revenue with a -212.3% profit margin.
Revenue growth is -19.8% quarter-over-quarter, while maintaining an operating margin of -143.0% and return on equity of -101.8%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Assembly Biosciences Inc (ASMB) Company Overview
About Assembly Biosciences Inc
Develops therapies for viral diseases.
The company focuses on developing therapeutic candidates for viral diseases, particularly targeting herpes simplex virus and hepatitis viruses. It generates revenue through collaboration agreements with other pharmaceutical companies, such as Gilead Sciences and BeiGene, which can provide funding and resources for clinical trials and drug development.
Assembly Biosciences has several promising candidates in various phases of clinical trials, indicating a robust pipeline. The company has a history of changing its name, having been previously known as Ventrus Biosciences, and was incorporated in 2005. Its headquarters is located in South San Francisco, California.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
65
CEO
Mr. Jason A. Okazaki
Country
United States
IPO Year
2010
Website
www.assemblybio.comAssembly Biosciences Inc (ASMB) Latest News & Analysis
ABI-4334 demonstrated a favorable safety profile and a half-life suitable for once-daily oral dosing, indicating potential for regular use in treatment.
Positive trial results for ABI-4334 suggest strong market potential and may lead to increased sales, enhancing the company's stock value and attracting investor interest.
Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have shown performance metrics that can be compared to their respective sector averages for the year.
Performance comparisons highlight relative strength or weakness in stock price, impacting investment decisions and potential market confidence in Assembly Biosciences and Adma Biologics.
Data on ABI-5366 and ABI-1179, new long-acting helicase-primase inhibitors for recurrent genital herpes, will be presented soon.
The presentation of data for ABI-5366 and ABI-1179 could impact stock prices and investor sentiment in the biotech sector, indicating potential breakthroughs in herpes treatment.
ABI-5366 is undergoing Phase 1a single ascending dosing trials in healthy participants, with interim data anticipated in Q3 2024.
The upcoming interim data on ABI-5366 could influence its market potential and investor sentiment, impacting stock prices and future funding opportunities.
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congressโข 2024
8 months agoAssembly Bio presented preclinical data on its helicase-primase inhibitors for genital herpes and a new entry inhibitor for hepatitis D at recent scientific conferences.
Positive preclinical data for Assembly Bio's herpes and hepatitis D candidates may enhance investor confidence, potentially leading to increased stock value and interest in future clinical trials.
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
8 months agoAssembly Biosciences, Inc. (Nasdaq: ASMB) reported its financial results for Q1 2024, focusing on its development of therapeutics for serious viral diseases.
Assembly Biosciences' Q1 financial results may indicate its growth trajectory and effectiveness in developing therapeutics, impacting investor confidence and stock performance.
Frequently Asked Questions About ASMB Stock
What is Assembly Biosciences Inc's (ASMB) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Assembly Biosciences Inc (ASMB) has a median price target of $35.50. The highest price target is $36.00 and the lowest is $35.00.
Is ASMB stock a good investment in 2025?
According to current analyst ratings, ASMB has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ASMB stock?
Wall Street analysts predict ASMB stock could reach $35.50 in the next 12 months. This represents a 149.8% increase from the current price of $14.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Assembly Biosciences Inc's business model?
The company focuses on developing therapeutic candidates for viral diseases, particularly targeting herpes simplex virus and hepatitis viruses. It generates revenue through collaboration agreements with other pharmaceutical companies, such as Gilead Sciences and BeiGene, which can provide funding and resources for clinical trials and drug development.
What is the highest forecasted price for ASMB Assembly Biosciences Inc?
The highest price target for ASMB is $36.00 from at , which represents a 153.3% increase from the current price of $14.21.
What is the lowest forecasted price for ASMB Assembly Biosciences Inc?
The lowest price target for ASMB is $35.00 from Dennis Ding at Jefferies, which represents a 146.3% increase from the current price of $14.21.
What is the overall ASMB consensus from analysts for Assembly Biosciences Inc?
The overall analyst consensus for ASMB is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $35.50.
How accurate are ASMB stock price projections?
Stock price projections, including those for Assembly Biosciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.